Production of a recombinant vaccine candidate against Burkholderia pseudomallei exploiting the bacterial N-glycosylation machinery

Vaccines developing immune responses toward surface carbohydrates conjugated to proteins are effective in preventing infection and death by bacterial pathogens. Traditional production of these vaccines utilizes complex synthetic chemistry to acquire and conjugate the glycan to a protein. However, glycoproteins produced by bacterial protein glycosylation systems are significantly easier to produce, and could possible be used as vaccine candidates. In this work, we functionally expressed the Burkholderia pseudomallei O polysaccharide (OPS II), the Campylobacter jejuni oligosaccharyltransferase (OTase), and a suitable glycoprotein (AcrA) in a designer E. coli strain with a higher efficiency for production of glycoconjugates. We were able to produce and purify the OPS II-AcrA glycoconjugate, and MS analysis confirmed correct glycan was produced and attached. We observed the attachment of the O-acetylated deoxyhexose directly to the acceptor protein, which expands the range of substrates utilized by the OTase PglB. Injection of the glycoprotein into mice generated an IgG immune response against B. pseudomallei, and this response was partially protective against an intranasal challenge. Our experiments show that bacterial engineered glycoconjugates can be utilized as vaccine candidates against B. pseudomallei. Additionally, our new E. coli strain SDB1 is more efficient in glycoprotein production, and could have additional applications in the future.


INTRODUCTION
Burkholderia pseudomallei, a Gram-negative saprophyte, is the causative agent for melioidosis and is endemic in Southeast Asia and Northern Australia (Cheng and Currie, 2005). It is highly resistant to harsh environmental pressures, and it is classified as a potential class B bioterrorism weapon due to its high infectivity when aerosolized (Silva and Dow, 2013). Several virulence factors have been identified, including multiple Type III and VI secretion systems, toxins, capsular polysaccharide, and lipopolysaccharide (LPS; Nandi and Tan, 2013). Two different LPS structures named O-polysaccharide (OPS) I and II are present in B. pseudomallei, and OPS II was shown to be required for serum resistance and virulence (Knirel et al., 1992;Perry et al., 1995;DeShazer et al., 1998). B. pseudomallei has an intrinsically high resistance to several different classes of antibiotics, which increases the potential danger of this organism. Due to the increasing prevalence of new resistance genes, and the increasing number of cases, new alternatives to treat and prevent melioidosis are required.
Immunization is one of the best available tools against infection, and it is significantly more cost effective than treatment after disease has occurred. Three main classes of vaccines are commercially produced. Live attenuated bacteria that have been shown to be highly effective as vaccine candidates however, drawbacks such as safety, reactogenicity, stability, and manufacturing remain problematic (Galen and Curtiss, 2013). Whole-cell-killed bacterial vaccines are easy to commercially manufacture, but have problems with stability, long-term protection, and present biosafety risks in the case of class III pathogens. Purified surface carbohydrates have been utilized as a vaccine candidate, but typically only produce short-term protection and are not effective in children or mature individuals (Lockhart, 2003). Traditional conjugate vaccines, where bacterial surface polysaccharides are chemically conjugated to a carrier protein, have been demonstrated to be highly effective. The best example is the Haemophilus influenzae type b conjugate vaccine, which has nearly eliminated infections in vast parts of the world (Pollard et al., 2009). However, manufacturing these conjugate vaccines requires complex synthetic chemistry for the attachment of the glycan to protein carriers. Additionally, the polysaccharides are either obtained from the target pathogen, which constitutes a major health hazard, or by laborious, chemical synthesis. Often, bacterial polysaccharides are too complex to be synthesized efficiently, making this process economically prohibitive. Finally, chemical attachment of the sugar to the carrier protein can result in large and heterogeneous conjugates, modifying the native structure, and thus decreasing the protective nature of the vaccine. Both live attenuated and killed bacterial vaccines have been tested against B. pseudomallei, but provide little to no protection against disease www.frontiersin.org and mortality in murine virulence models (Peacock et al., 2012). Additionally, since B. pseudomallei requires class III biosafety facilities, manufacturing glycoconjugates containing glycans from its native host is challenging and possibly hazardous. Recently, it has been demonstrated a protein chemically conjugated with the B. pseudomallei OPS and CPS was able to increase survival against B. pseudomallei infection (Scott et al., 2014). Additionally, protection has been demonstrated using B. thailandensis E555 as a live vaccine due to homology of CPS structures (Scott et al., 2013).
A novel method of synthesizing conjugate vaccines is through the exploitation of the protein glycosylation machineries of bacteria (Iwashkiw et al., 2012;Cuccui et al., 2013;Wetter et al., 2013). The cornerstone of bacterial glycosylation is the oligosaccharyltransferase (OTase) enzymes, which covalently attach glycan structures to either asparagine (N-linked) or serine/threonine (O-linked) residues . OTases have high substrate promiscuity, and thus can transfer a wide range of glycan structures to acceptor proteins, in a process called OTase-dependent glycosylation. The best characterized Nglycosylation system in bacteria is from Campylobacter jejuni . Briefly, a unique initiating glycosyltransferase attaches a nucleotide-activated monosaccharide-1P to the lipid carrier undecaprenyl phosphate (Und-P) in the cytoplasmic face of the inner membrane. Subsequently, a series of other glycosyltransferases attach additional monosaccharides to first residue, and when completed, the lipid-linked oligosaccharide (LLO) is translocated to the periplasmic face of the inner membrane by a flippase. Finally, PglB (N-OTase) covalently attaches the glycan to asparagine residues with the sequon D/E-X-N-Y-S/T (X,Y =P; Kowarik et al., 2006). Earlier studies demonstrated PglB has relaxed glycan specificity, allowing the transfer of a vast array of glycans, including O antigens, to acceptor proteins (Feldman et al., 2005). It was later shown that O-OTases share this feature (Faridmoayer et al., 2008). Thus, bacterial glycosylation systems can be exploited to synthesize novel glycoconjugates for vaccination and diagnostic purposes as previously demonstrated (Ihssen et al., 2010;Iwashkiw et al., 2012;Cuccui et al., 2013;Wetter et al., 2013;Wacker et al., 2014). Glycoconjugates produced by this method are significantly less expensive, less challenging to produce, and produce less hazardous waste than conventional chemical methods.
In this work, we demonstrate that the biosynthesis of the B. pseudomallei OPS II can be reconstituted in Escherichia coli (E. coli). Successful generation of the conjugate required the expression of the corresponding B. pseudomallei OPS II genes in an E. coli strain lacking both the waaL ligase and wecA initiating glycosyltransferase (SDB1). This glycoconjugate, when injected into mice, was able to develop a directed IgG immune response toward B. pseudomallei, and provide partial protection against infection in a murine model of melioidosis.

BACTERIAL STRAINS, PLASMIDS, AND GROWTH CONDITIONS
Escherichia coli strains were grown on LB broth at 37 • C. Trimethoprim (100 μg/ml), spectinomycin (80 μg/ml), and ampicillin (100 μg/ml) were added to the media for plasmid selection as needed. The strains and plasmids used are listed in Table 1.

WESTERN BLOTTING
Glycan expression and glycosylation were analyzed by SDS-PAGE on 10% gels. The gels were electroblotted onto a nitrocellulose membrane via semi-dry membrane transfer and analyzed with antibodies α-His (Santa Cruz Biotechnology) and α-BPs OPSII glycan kindly provided by Dr. Joanne Prior (1:1,000). Membranes were visualized using the Odyssey Infrared Imaging System (Li-Cor Biosciences, USA).

CLONING AND EXPRESSION OF Burkholderia pseudomallei TYPE II OPS
To obtain the plasmid expressing the type II O-antigen polysaccharide of Burkholderia pseudomallei under an arabinose promoter we used the pCC1FOS-BPF16β_E10 vector kindly provided by Professor R. Titball (University of Exeter), which contains the LPS cluster of B. pseudomallei K96243, coordinates 3191324-3229257. The pCC1FOS-BPF16β_E10 vector was digested with NheI, KpnI, and PciI to get an 8673 bp fragment, corresponding to genes between rmlD and wbiC, and with SnaBI and KpnI to get a 9367 bp fragment that includes the genes between wbiC and wbiI. These two fragments containing the 15 genes required for B. pseudomallei type II OPS expression were inserted into pBAD24 digested with NheI and SmaI. Arabinose-dependent expression of the type II O-antigen was confirmed by Western blot.

CONSTRUCTION OF SDB1 waaL AND wecA DEFICENT STRAIN
Construction of SDB1 strain was done using the P1 transduction protocol adapted from Thomason et al. (2007). The P1 bacteriophage was first grown on the strain (BW25113 rfe::kan.) from the Keio collection library (Baba et al., 2006). This strain has a kanamycin-resistant cassette on the wecA gene as a donor. The resulting phage lysate was used to infect the recipient strain CLM24 ( waaL). Recombinant strains were confirmed by PCR using the oligonucleotides rfe for comp (5 -GCAATGACCAAGACCAATGACG-3 ) and rfe rev comp (5 -GCTGCTGCGAGTAATATCCC-3 ). The kanamycin cassette was removed using the FLP recombinase expressed from pFLP2.

PRODUCTION AND PURIFICATION OF GLYCOSYLATED AcrA
SDB1 strain transformed with C. jejuni PglB (pMAF10), AcrA (pIH18), and BPs type II O-antigen (pEQ3) was grown overnight at 37 • C. Culture was reinnoculated 1/33 into fresh LB media using a culture/flask ratio 1:10. After 2 h at 37 • C with shaking at 200 rpm, the cultures were induced with 0.1 mM isopropyl 1-thio-β-Dgalactopyranoside (IPTG; Sigma) and 0.2% (w/v) L-(+)-arabinose (MP Biomedicals). To increase the glycosylation yield in SDB1, we also added MnCl 2 (4 mM). Five hours after induction at 37 • C, arabinose was added again to ensure PglB expression. Cells were harvested by centrifugation after an overnight induction period and the periplasmic extract containing the glycoproteins was extracted using a lysozyme treatment as described previously (Iwashkiw et al., 2012). For purification, the periplasmic fraction was equilibrated with 1/9 vol 10× loading buffer (0.1 M imidazole, 3 M NaCl, 0.2 M Tris-HCl, pH 8.0) and subjected to a Ni 2+ affinity chromatography as described (Iwashkiw

SUGAR QUANTIFICATION OF GLYCOPROTEINS
The protocol was adapted from Dubois et al. (1956). In a small glass tube was mixed 10 μl of sample, 90 μl of ddH 2 O, and 100 μl of freshly made 5% phenol in ddH 2 O. Then 1 ml of concentrated H 2 SO 4 was briskly added into the mixture and immediately vortex for several seconds. An orange color with intensity proportional to concentration began to develop and reached a maximum about 2 h at 30 • C. The samples were read against glucose standards at OD 500.

VACCINATION
BALB/c mice (n = 5 per group, 6-week-old female) were immunized with three doses of purified recombinant bioconjugate vaccine, carrier protein, or gamma-irradiated killed whole cells (3 × 10 4 Burkholderia pseudomallei K96234), via the intraperitoneal route (i.p.) over 6 weeks. The doses were administered with Imject Alum Adjuvant (Thermo Scientific), not used with whole killed cells or when noted. Sera samples were collected for antibody analysis, prior to immunization 2 weeks after vaccination and boost. The antibody titre of total IgG was analyzed by ELISA. Briefly, wells of microtiter plates were coated (18 h, 4 • C) with gamma-irradiated whole Burkholderia pseudomallei cells at a 1/100 dilution in 100 μl of coating buffer (0.05 M Na 2 CO 3 , 0.05 M NaHCO 3 , pH 9.6) and were then blocked with 2% (w/v) BSA in PBS for 2 h at 37 • C. Sera samples at a 1/200 dilution in 100 μl of antibody dilution buffer [2% (w/v) BSA, 0.1% (v/v) Tween 20] were incubated for 1 h at 37 • C. HRP-conjugated goat antimouse IgG at a 1/8000 in antibody dilution buffer was added for 1 h at 37 • C and then the reaction was visualized by the addition of 100 μl chromogenic substrate (ultra-TMB) for 5 min.
The reaction was stopped with 100 μl H 3 PO 4 and absorbance at 405 nm was measured using ELISA plate reader. Plates were washed five times with washing buffer [0.1% (v/v) Tween 20] after each step.

INTRANASAL CHALLENGE MODEL
The murine melioidosis infection model used was carried out under ABSL-3 containment practices. Briefly, female BALB/c mice were challenged via the i.n. route (50 μl) with approximately 2 × 10 3 CFU (approximately 10-12 LD 50 ) of B. pseudomallei K96243. Mice were weighed prior to inoculation and monitored for 21 days post-infection. Mice were anesthetized, held vertically, and 50 ml of the inoculum was released into the nares for inhalation. Following challenge, the inoculum was back titrated on agar plates to confirm delivered dose. Using this model, control mice died or were euthanized according to predetermined humane end points 3-6 days post-challenge.

STATISTICS
Survival curves were generated by use of Kaplan-Meier estimators. The survival distributions of each treatment group vs. control protein carrier group were compared by unpaired T test or Mann-Whitney test using GraphPad Prism version 6.0. www.frontiersin.org

ETHICS STATEMENT
This study was carried out in accordance with the Canadian animal care guidelines. The protocols were approved by the Animal Care and Use Committees of Defence Research and Development Canada. Mice were anesthetized by intraperitoneal injection of a sodium pentobarbital solution.

CLONING AND EXPRESSION OF THE B. pseudomallei K96243 O ANTIGEN POLYSACCHARIDE II (OPS II) LOCUS IN E. coli
Previous work identified a region consisting of 21 potential open reading frames, and further investigation identified a cluster of 15 genes required for the biosynthesis of B. pseudomallei K96243 OPS II (Figure 1A; DeShazer et al., 1998). A previous study demonstrated by NMR analysis that the structure of OPS II is a polymer of a disaccharide repeating structure composed of -3-)-β-D-glucopyranose-(1-3)-α-L-6-deoxy-talopyranose-(1-, with variable O-methyl and O-acetyl modifications ( Figure 1B; Perry et al., 1995). In order to recombinantly express the B. pseudomallei OPS II in E. coli, the 15 essential genes were subcloned (genes rmlB to wbiI) from the plasmid pCC1FOS-BPF16β_E10 by restriction digest into the arabinose inducible expression vector pBAD24, generating pEQ3 ( Figure 1A). Expression of the B. pseudomallei OPS II in E. coli CLM37 was visualized by Western blot as a typical ladder of immunoreactive bands, confirming the production of the carbohydrate structure ( Figure 1C).

GENERATION OF AN E. coli STRAIN OPTIMIZED FOR OPS II PRODUCTION AND PROTEIN GLYCOSYLATION
We attempted to generate a N-linked glycoprotein with the OPS II by exploiting the C. jejuni N-glycosylation system as previously described (Ihssen et al., 2010;Iwashkiw et al., 2012;Cuccui et al., 2013;Wetter et al., 2013). In earlier work, N-glycosylated AcrA was synthesized in E. coli by co-expression of C. jejuni PglB and AcrA with an appropriate carbohydrate structure. We therefore expressed PglB (pMAF10), AcrA (pIH18), and the B. pseudomallei OPS II antigen (pEQ3) in both a traditional expression (EPI300) and wecA-(CLM37) strains and tested for glycosylation by Western blot. We were unable to detect any evidence of glycosylation of purified AcrA (data not shown). One issue with exploiting O antigens using protein glycosylation may be the precursor can also be used by the WaaL ligase in E. coli, thus siphoning off the substrate, and decreasing the glycosylation efficiency (Figure 2). Additionally, E. coli strains express the initiating glycosyl transferase (wecA), which transfers a GlcNAc onto the undecaprenyl-diphosphate (Und-PP) carrier. This would interfere with the synthesis of the glycan of interest onto the same lipid if the first sugar in the structure is not a GlcNAc, as in the case of the OPS II. We hypothesized that deletion of WaaL and WecA would result in an increased efficiency of protein glycosylation ( Figure 2C).
We therefore constructed the E. coli wecA − waaL − mutant strain SDB1. Using the KEIO strain collection (Baba et al., 2006), the wecA mutation was transduced into CLM24, an E. coli waaL mutant (Feldman et al., 2005), creating SDB1. To functionally confirm the double mutation, we analyzed the LPS produced by SDB1 transformed with plasmid pJHCV32 (Figure 3). The plasmid pJHCV32 drives the constitutive expression of the E. coli O7 antigen, but relies on the chromosomal copy of the glycosyltransferase WecA (Valvano and Crosa, 1989). Expression in trans of either WecA or WaaL individually in this background did not result in the production of a smooth LPS containing the O7 antigen (lanes 1-8). However, when both genes were co-expressed in SDB1, we observed the characteristic polymerization of O antigen previously observed for the E. coli O7 LPS (lanes 9 and 10), confirming the creation of the double mutation.

IN VIVO SYNTHESIS AND PURIFICATION OF AN N-LINKED GLYCOCONJUGATE WITH THE Burkholderia OPSII GLYCAN
To create an N-linked glycoconjugate, we transformed the E. coli strain SDB1 with the pEQ3 (OPS II), pMAF10 (PglB), and pIH18 (AcrA). Cultures of the transformed strain were grown  and induced as required, and AcrA was purified from periplasmic extracts by Ni 2+ affinity chromatography. To determine if AcrA was glycosylated, we analyzed the purified protein by either Western blot with antibodies specific to either AcrA or OPS II, or Coomassie stain, and when visualized together, we observed an overlap of the signal, suggesting glycosylation of AcrA with the OPSII glycan (Figure 4).
To confirm AcrA was glycosylated with the B. pseudomallei OPS II carbohydrate, we employed mass spectrometry (MS) techniques. The purified glycoprotein was tryptically digested insolution, and the resulting peptides were examined by LC-ESI-Q-TOF MS and MS/MS. Manual analysis of the MS data (MassLynx; Waters Corporation) revealed a peak with an m/z 1152.06 3+ , and further inspection of this peak by MS/MS revealed a glycopeptide that corresponded to the previously identified second glycosylation site of AcrA (AVFDNNNSTLLPGAFATITSEGFIQK; m/z 2754.1) with the addition of an m/z 700.2 modification (Figure 5). De novo peak annotation identified the modification to be a tetramer of 188-162-188-162. The mass of 188 Da is consistent with an O-acetyl deoxyhexose residue, and the 162 Da is consistent with a hexose residue. We were also able to identify in the low-molecular region both an individual O-acetyl deoxyhexose (189.0 Da), and a subunit of the dimer with a mass of 351.1 Da. Our MS characterization of the B. pseudomallei OPS II glycan is consistent with the previously published data identifying it to be a polymer of dimers of O-acetylated deoxytalose and glucose (Perry et al., 1995). These data combined with the immunoreactivity of our glycoconjugate to the B. pseudomallei OPS II antibody confirm that we were able to synthesize and glycosylate AcrA with the correct glycan structure in E. coli SDB1.
FIGURE 4 | Analysis of purified AcrA by Western Blot. SDB1 transformed with pMAF10 (pglB), pIH18 (acrA), and pEQ3 (OPS II) were grown (+/−) induction of OPS II, harvested, and AcrA was purified by Ni 2+ -NTA affinity chromatography. Purified glycoconjugate was separated on 10% SDS-PAGE and analyzed by western blot (5 μl) or Coomassie stain (15 μl). A high-molecular-weight ladder is co-detected by both α-His and α-Glycan antibodies, and overlap of the two signals strongly suggests glycosylation of AcrA. Staining of the purified protein is observed by Coomassie stain.

MICE INJECTED WITH PURIFIED N-LINKED BIOGLYCOCONJUGATE DEVELOPED A PARTIALLY PROTECTIVE IgG IMMUNE RESPONSE TOWARD B. pseudomallei WHOLE CELLS
To evaluate the potential use of the glycoprotein as conjugate vaccine, the purified AcrA containing OPS II was injected intraperitoneally into mice to measure the immune response compared to whole-cell-killed B. pseudomallei. Groups of five mice were injected with PBS, unglycosylated AcrA as control, glycoconjugate in different quantities, or whole-cell-killed cells.
The IgG immune response was tested by ELISA against wholecell extracts of B. pseudomallei (Figure 6). All test groups were compared to the PBS control, and showed no initial immune response toward B. pseudomallei in the pre-injection sera. The AcrA-injected group had a slight increase in IgG response, but did not increase after additional boosts. A significant increase in IgG response was observed in each of the glycosylated test groups after the primary vaccination, with varying degrees of improvement in immune response after a second and third boost. The best immune response was observed in the mice injected with whole-cell lysates of B. pseudomallei had a significantly stronger immune response as compared to the glycoconjugate sera, but this was expected as whole cells were use as antigen for the ELISA.
We next tested the immunized mice for a preliminary evaluation of the efficacy of the glycoconjugate. We employed an intranasal murine melioidosis model against B. pseudomallei infection with a dose of 12× LD 50 (Figure 7). Mice vaccinated with only protein carrier died or were euthanized according to predetermined humane end points after 6 days. For the PBS-injected control group, 80% of the mice died or were euthanized after 6 days, and one mouse survived until day 13 of the challenge. All of the mice vaccinated with the glycoconjugate showed a significant increase in survival time as compared to the control protein carrier group. However, contrary to the ELISA results that showed the best IgG immune response in mice vaccinated with 2 μg of glycosylated AcrA, 40% of the mice survived until day 12, with the remaining being sacrificed on day 14. Mice injected with 1 μg of glycoprotein without any adjuvant saw survival until day 18, while one mouse vaccinated with 1 μg survived until day 22. The difference in mean time to death was not statistically significant between the groups receiving the various glycoprotein preparations. In comparing our glycoconjugate to whole-cell-killed bacteria as vaccine candidates, we observed highly similar survival of the mice, with all mice succumbing to infection by day 18 of the challenge. Overall, these results demonstrate that the N-glycoconjugate containing the B. pseudomallei OPS II is capable of providing partial immune protection against a 12 × LD 50 dose, and it is comparable to whole-cell-killed bacteria in protection against infection.

DISCUSSION
Due to a combination of factors including the increasing number of reported cases of B. pseudomallei infections, the risk posed by the bacterium as a potential biological warfare agent, and an absence of an effective vaccine, we explored the possibility that by exploiting the N -linked glycosylation system of C. jejuni, we could produce a glycoconjugate vaccine containing the OPS II of B. pseudomallei. This strategy was only demonstrated in a few cases (Iwashkiw et al., 2012;Cuccui et al., 2013;Wetter et al., 2013). Since B. pseudomallei is a biosafety class III agent we were unable to directly exploit the native OPS II by expressing the N -glycosylation system in the host as previously shown (Iwashkiw et al., 2012). Instead, we utilized previous knowledge of the genetic loci responsible for the biosynthesis of OPS II (DeShazer et al., 1998), and subcloned the key 15 genes into an E. coli expression vector. We observed high levels of expression of the OPS II in E. coli strains Frontiers in Microbiology | Microbial Physiology and Metabolism by Western blot, and attempted to create the glycoconjugate in a basic expression and wecA-E. coli strains as previously described (Ihssen et al., 2010;Cuccui et al., 2013;Wetter et al., 2013). We did not observe any evidence of glycosylation, and hypothesized that the OPS II was being utilized exclusively to modify the LPS. Therefore, we engineered an E. coli strain (SDB1) lacking both the waaL ligase, and wecA. Construction of the SDB1 strain was confirmed by expressing either or both WecA and WaaL with a plasmid encoding the E. coli O7 LPS cluster that lacks WecA homolog. Analysis of LPS extractions by silverstain showed that the O7 antigen structure was only transferred to lipid A in the presence of both enzymes. Our engineered strain in theory should be able to produce the OPS II-AcrA glycoconjugate with high efficiency due to no other competition for either the undecaprenyl-phosphate lipid carrier by WecA or the OPS II-Und-PP substrate from WaaL.
We showed that SDB1 produced the desired glycoconjugate when OPS II (pEQ3), PglB (pMAF10), and AcrA (pIH18) were coexpressed. The generation of the conjugate was shown via Western blot and MS. Interestingly, glycosylation of AcrA required the addition of MnCl 2 to the media. Although Mn 2+ is required for PglB activity and was observed in the active site of the crystal structure (Lizak et al., 2011), we did not have to add Mn 2+ to obtain glycosylated proteins in previous experiments. The direct relationship between its addition and glycosylation efficiency is unclear. The MS examination of the purified glycoconjugate revealed the presence of a tetrameric glycan moiety corresponding to two repeats of O-acetylated deoxyhexose and hexose, in agreement with previously published characterization of the structure (Perry et al., 1995). Interestingly, previous work has shown that the C. jejuni OTase PglB can only transfer glycans with a reducing monomer with an N -acetyl group, whereas the B. pseudomallei OPS II structure has been shown to possess an O-acetyl modification. This finding expands our knowledge on the substrate specificity of PglB. We did not observe any larger glycan structures that were detected by Western blot, but this could be due to limitations of our MS instruments. Most of the Wzy-independent glycans require an adapter composed of two monosaccharides linking the lipid carrier to the polymeric structure (Whitfield, 2006;Greenfield and Whitfield, 2012). The finding that the O-acetylated deoxytalose appears to be directly linked to the protein indicates that a linker glycan (proposed in Figure 1A as X1 and X2) is not present in the OPS II structure. Our experiments demonstrate that in the genetically engineered strain SDB1, we were able to produce a glycoconjugate with the B. pseudomallei OPS II carbohydrate.
We carried out preliminary experiments to determine if our glycoconjugate could be utilized as a vaccine against B. pseudomallei. We injected different quantities of the glycoconjugate into mice. We observed virtually no response toward B. pseudomallei for the mice injected with the protein carrier alone, whereas a significantly stronger response from the mice injected with all groups of the glycoconjugate. Interestingly, an intermediate response was observed in the 1 μg glycoconjugate groups, regardless of the addition of an adjuvant. We then challenged the vaccinated mice with B. pseudomallei K96243, and after 6 days post challenge, none of the carrier control injected mice survived, whereas survival was observed each of the glycoconjugate groups, with the longest survival in the 1 μg group, irrespective of the addition of an adjuvant. Why lower levels of antibody production resulted in better protection remains unknown, although these differences in protection were not statistically significant between groups receiving www.frontiersin.org FIGURE 6 | ELISA of the IgG immune response of immunized mice toward whole-cell extracts of B. pseudomallei. All data were normalized to the PBS-injected control mice, and no response was observed in all groups prior to immunization. A low level of response was observed at a consistent level for the unglycosylated AcrA control, whereas all test groups injected with glycosylated AcrA had a significant IgG response. The results are the median of five mice in each test group. the glycoprotein. It is possible that the carrier protein, AcrA, due to its high immunogenic nature, acts as an adjuvant itself. This could also possibly explain why both of the 1 μg groups while having a lower detected IgG immune response compared to the 2 μg group have a longer survival period. Our results are consistent with these previous studies with the non-protected mice succumbing to infection after ∼1 week (Nelson et al., 2004;Su et al., 2010;Nieves et al., 2011). Interestingly, our initial studies with the glycoconjugate gave similar protection levels to wholecell-killed B. pseudomallei. Further optimization of our vaccine candidate is currently undergoing. This includes testing different amounts of conjugate, and replacing the acceptor protein from AcrA of C. jejuni to a B. pseudomallei protein, which may enhance the immunogenicity of the conjugate.
Several other studies have been published attempting to develop a vaccine against B. pseudomallei (reviewed in Silva and Dow, 2013). Many of these vaccine candidates have dealt with either attenuated strains, whole-cell-killed bacteria, or purified proteins directly from B. pseudomallei, which requires class III biosafety facilities, and would lead to higher significant problems for commercialization of the product. Other groups attempted to recombinantly express and purify B. pseudomallei proteins in E. coli, with limited success. However, our work has demonstrated that the OPS II carbohydrate of B pseudomallei can be functionally expressed in E. coli, and be utilized by PglB to create a glycoconjugate that is partially protective against infection. Glycoengineered therapeutics are simple to produce, cost effective, and have been demonstrated to provide long-term protection against several pathogens. Additionally, previous work has used a similar glycoconjugate with the Y. enterocolitica O9 O-antigen as a diagnostic tool (Iwashkiw et al., 2012). Conjugation of the glycoconjugate to magnetic nanobeads has shown significant promise in detection of disease in cattle and human sera samples (Ciocchini et al., 2013(Ciocchini et al., , 2014. A similar system may have future potential for diagnosing individuals infected with B. pseudomallei.
In summary, we have demonstrated that the OPS II glycan of B. pseudomallei can be functionally expressed in E. coli. Additionally, this glycan was transferred to the carrier protein AcrA by the OTase PglB, both from C. jejuni, to generate a glycoconjugate. We also described a novel E. coli strain SDB1 which lacks wecA and waaL, resulting in a higher efficiency of glycosylation as compared to previously used strains. Mice injected with this glycoprotein were able to develop a long-term IgG immune response, and showed significantly longer survival when challenged with B. pseudomallei as compared to the naive controls. This new biologically engineered strain may be used for the future creation of commercial bioglycoconjugate therapeutics, and glycoconjugate may have future potential for diagnostic applications or vaccination against B. pseudomallei infections.